Overview
Ru⁴⁺-Doxorubicin is a targeted MDC designed for solid tumor environments. Ruthenium (IV) allows for pH-responsive drug release, enabling the complex to remain stable in blood but activate in acidic microenvironments such as those found in tumors.
Mechanism of Action
- Ruthenium ion undergoes redox-based activation in low-pH conditions
- Doxorubicin intercalates DNA and inhibits topoisomerase II once released
- Minimal release in healthy tissues reduces off-target cytotoxicity
Key Properties
- pH-triggered release below pH 6.8
- Reduced cardiotoxicity profile
- Longer circulation half-life
Application
Therapeutic Class: Cancer
Indicated for breast, ovarian, and colorectal cancers with acidic tumor cores.
Oncology
pH-Activated
Development Stage
IND-Enabling Studies
Further Information
To request IND-enabling data or co-development partnership materials, contact our research team.
Contact Us